📊 SUPN Key Takeaways
Is Supernus Pharmaceuticals, Inc.. (SUPN) a Good Investment?
Supernus maintains financial stability through a debt-free balance sheet, strong liquidity, and positive free cash flow generation of $46M. However, the company is operationally unprofitable with -8.7% operating margins and deteriorating earnings per share (-151.5% YoY), indicating structural challenges in reaching profitability despite 8.6% revenue growth. This is a turnaround story requiring demonstrated operating leverage and path to profitability.
Why Buy Supernus Pharmaceuticals, Inc.. Stock? SUPN Key Strengths
- Zero long-term debt with $1.1B stockholders equity provides significant financial flexibility
- Strong liquidity position: current ratio 1.90x, quick ratio 1.57x, with $128.4M cash reserves
- Positive free cash flow of $46M despite GAAP losses, demonstrating cash generation ability
- Revenue growth of 8.6% YoY indicates market demand for pharmaceutical products
- Capital-light business model with minimal CapEx ($1.3M), preserving cash for operations
SUPN Stock Risks: Supernus Pharmaceuticals, Inc.. Investment Risks
- Sustained operating losses with -8.7% operating margin on $719M revenue base, burning ~$62M annually
- Deteriorating earnings per share (-151.5% YoY) signaling worsening per-share economics and potential share dilution
- No visible path to profitability in current financial data; net losses persist despite revenue growth
- Unable to assess gross margin (N/A) - unclear whether issues stem from product-level margins or operating expenses
- Significant insider activity (34 Form 4 filings in 90 days) may suggest management uncertainty
Key Metrics to Watch
- Operating margin trajectory - critical to monitor when/if company reaches operating profitability
- Gross margin and product mix - need visibility into unit economics by product line
- EPS stabilization and reversal of deterioration trend
- Operating cash flow sustainability and whether positive FCF can continue amid losses
- SG&A expense ratio - must show operational leverage as revenue grows
Supernus Pharmaceuticals, Inc.. (SUPN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Supernus Pharmaceuticals, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SUPN Profit Margin, ROE & Profitability Analysis
SUPN vs Healthcare Sector: How Supernus Pharmaceuticals, Inc.. Compares
How Supernus Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Supernus Pharmaceuticals, Inc.. Stock Overvalued? SUPN Valuation Analysis 2026
Based on fundamental analysis, Supernus Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Supernus Pharmaceuticals, Inc.. Balance Sheet: SUPN Debt, Cash & Liquidity
SUPN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Supernus Pharmaceuticals, Inc..'s revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.02 reflects profitable operations.
SUPN Revenue Growth, EPS Growth & YoY Performance
SUPN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $175.7M | $124.0K | $-0.61 |
| Q2 2025 | $165.5M | $124.0K | $0.19 |
| Q1 2025 | $143.6M | $124.0K | $0.00 |
| Q3 2024 | $153.9M | $124.0K | $0.00 |
| Q2 2024 | $135.6M | $124.0K | $-0.02 |
| Q1 2024 | $143.6M | $124.0K | $0.00 |
| Q3 2023 | $153.9M | $141.0K | $0.00 |
| Q2 2023 | $135.6M | -$831.0K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Supernus Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
SUPN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Supernus Pharmaceuticals, Inc.. (CIK: 0001356576)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SUPN
What is the AI rating for SUPN?
Supernus Pharmaceuticals, Inc.. (SUPN) has an AI rating of HOLD with 52% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SUPN's key strengths?
Claude: Zero long-term debt with $1.1B stockholders equity provides significant financial flexibility. Strong liquidity position: current ratio 1.90x, quick ratio 1.57x, with $128.4M cash reserves.
What are the risks of investing in SUPN?
Claude: Sustained operating losses with -8.7% operating margin on $719M revenue base, burning ~$62M annually. Deteriorating earnings per share (-151.5% YoY) signaling worsening per-share economics and potential share dilution.
What is SUPN's revenue and growth?
Supernus Pharmaceuticals, Inc.. reported revenue of $719.0M.
Does SUPN pay dividends?
Supernus Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find SUPN SEC filings?
Official SEC filings for Supernus Pharmaceuticals, Inc.. (CIK: 0001356576) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SUPN's EPS?
Supernus Pharmaceuticals, Inc.. has a diluted EPS of $-0.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SUPN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Supernus Pharmaceuticals, Inc.. has a HOLD rating with 52% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SUPN stock overvalued or undervalued?
Valuation metrics for SUPN: ROE of -3.6% (sector avg: 15%), net margin of -5.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SUPN stock in 2026?
Our dual AI analysis gives Supernus Pharmaceuticals, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SUPN's free cash flow?
Supernus Pharmaceuticals, Inc..'s operating cash flow is $47.3M, with capital expenditures of $1.3M. FCF margin is 6.4%.
How does SUPN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.4% (avg: 12%), ROE -3.6% (avg: 15%), current ratio 1.90 (avg: 2).